These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
487 related items for PubMed ID: 29712685
1. Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. Liu Z, McMichael EL, Shayan G, Li J, Chen K, Srivastava R, Kane LP, Lu B, Ferris RL. Clin Cancer Res; 2018 Sep 15; 24(18):4529-4538. PubMed ID: 29712685 [Abstract] [Full Text] [Related]
7. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL. Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4345-54. PubMed ID: 17671115 [Abstract] [Full Text] [Related]
9. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines. Liu J, Zhang S, Hu Y, Yang Z, Li J, Liu X, Deng L, Wang Y, Zhang X, Jiang T, Lu X. J Immunother; 2016 May 01; 39(4):171-80. PubMed ID: 27070448 [Abstract] [Full Text] [Related]
10. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers. Suzuki S, Ogawa T, Sano R, Takahara T, Inukai D, Akira S, Tsuchida H, Yoshikawa K, Ueda R, Tsuzuki T. Cancer Sci; 2020 Jun 01; 111(6):1943-1957. PubMed ID: 32304268 [Abstract] [Full Text] [Related]
15. Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy. Puntigam LK, Jeske SS, Götz M, Greiner J, Laban S, Theodoraki MN, Doescher J, Weissinger SE, Brunner C, Hoffmann TK, Schuler PJ. Int J Mol Sci; 2020 Jul 22; 21(15):. PubMed ID: 32707816 [Abstract] [Full Text] [Related]
16. Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer. Gadwa J, Bickett TE, Darragh LB, Knitz MW, Bhatia S, Piper M, Van Court B, Bhuvane S, Nguyen D, Nangia V, Kleczko EK, Nemenoff RA, Karam SD. J Immunother Cancer; 2021 Mar 22; 9(3):. PubMed ID: 33789881 [Abstract] [Full Text] [Related]
17. Targeting STAT3 Abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma. Huang L, Xu Y, Fang J, Liu W, Chen J, Liu Z, Xu Q. Front Immunol; 2021 Mar 22; 12():654749. PubMed ID: 33936081 [Abstract] [Full Text] [Related]
18. TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas. Li Z, Liu X, Guo R, Wang P. Tumour Biol; 2017 May 22; 39(5):1010428317698352. PubMed ID: 28475007 [Abstract] [Full Text] [Related]